Zynex Updates Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) has revised its earnings guidance for the first quarter of 2025. The company has announced an expected earnings per share (EPS) of -0.30 for the upcoming period. This is in stark contrast to the consensus estimate from analysts, which projected an EPS of 0.06. Additionally, Zynex provided revenue guidance of $30.0 million, which is also significantly lower than the consensus estimate of $53.5 million.

Analysts' Expectations on Growth

In a separate development, HC Wainwright maintained a "buy" rating on Zynex shares and established a price target of $17.00 in their report dated December 6th.

Zynex's Stock Performance

During midday trading on Tuesday, shares of Zynex (NASDAQ:ZYXI) experienced a decline of $0.17, reaching a price of $7.00. Approximately 119,612 shares changed hands, which is above the average trading volume of 111,921 shares. The market capitalization of Zynex stands at $222.92 million, with a price-to-earnings (P/E) ratio of 46.67 and a beta of 0.81. The company has a debt-to-equity ratio of 1.66, along with a quick ratio of 3.15 and a current ratio of 3.94. Over the past year, Zynex's stock has traded between a low of $5.44 and a high of $13.19. The 50-day moving average is $7.74, while the 200-day moving average is $8.02.

Recent Earnings Report

Zynex previously revealed its quarterly earnings results on March 11th. The company reported an EPS of -0.02, which fell short of the analysts' expectation of 0.09 by $0.11. Zynex recorded a net margin of 2.49% and a return on equity of 13.05%. In the same quarter the previous year, Zynex had reported an EPS of 0.04. Analysts predict that Zynex will achieve an average EPS of 0.20 for the current fiscal year.

Insider Trading Activity

In other news related to Zynex, CFO Daniel J. Moorhead sold 10,000 shares of the company on March 3rd at an average price of $7.15, amounting to a total transaction value of $71,500. Following this sale, the CFO now holds 10,050 shares valued at approximately $71,857.50. This transaction represents a 49.88% decrease in their position. Details were disclosed in a filing with the SEC. In the previous quarter, insiders traded 30,000 shares of the company, totaling around $227,100, indicating that insiders hold 52.13% of the stock.

Overview of Zynex, Inc.

Zynex, Inc., along with its subsidiaries, specializes in the design, manufacturing, and marketing of medical devices aimed at treating chronic and acute pain, as well as enhancing muscle activation and exercise through electrical stimulation. Their product lineup includes devices such as NexWave, a dual-channel multi-modality interferential current and electrical stimulation device marketed to medical professionals, NeuroMove for electromyography and electric stimulation, InWave for treating female urinary incontinence, and both E-Wave and M-Wave NMES devices.

Additional Insights

• Discover five stocks we prefer over Zynex
• Learn about electric vehicle stocks and how to capitalize on them
• NVIDIA stock appears significantly undervalued—find out why
• Natural gas prices are rising, and here are stocks that could benefit
• Reasons why Oracle stock is a strong buy for the long term
• Understanding special dividends
• Updates on U.S. stocks compared to foreign markets: Explore ETF opportunities

Earnings, Stocks, Zynex